111 Capital’s Novavax NVAX Stock Holding History

111 Capital’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-23,533	Closed	-$148K	–	621
2025 Q2	$148K	Buy	+23,533	New	+$156K	0.03%	466

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

111 Capital's NVAX Position: Q3 2025 in Review

111 Capital sold out of Novavax (NVAX) in Q3 2025, closing a stake of 23,533 shares — an estimated $148K sold.

111 Capital first reported a position in NVAX in Q2 2025 and held it in 1 quarter. The position peaked at $148K in Q2 2025. 249 funds tracked by Wall St. Rank hold NVAX as of Q3 2025.

111 Capital reported no remaining Novavax position as of Q3 2025 after selling out during the quarter.
111 Capital sold 23,533 Novavax shares in Q3 2025, an estimated $148K.
111 Capital first reported a position in Novavax in Q2 2025 and held it in 1 quarter.
111 Capital's Novavax position peaked at $148K in Q2 2025.
249 funds tracked by Wall St. Rank held Novavax as of Q3 2025.

Based on 111 Capital's 13F filing for Q3 2025, filed 12 Nov 2025.